Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. (TELA) provides investors and medical professionals with centralized access to official announcements and market-moving developments for this innovative MedTech company. Our news hub tracks the commercial-stage company's progress in soft tissue reconstruction, including product launches, clinical trial updates, and strategic partnerships.
Discover timely updates on TELA Bio's OviTex portfolio advancements, regulatory milestones, and financial performance. The resource aggregates press releases related to hernia repair innovations, abdominal wall reconstruction techniques, and plastic surgery solutions while maintaining strict editorial neutrality.
Key content categories include FDA clearances, surgeon collaboration initiatives, earnings reports, and leadership updates. Bookmark this page for unfiltered access to primary source materials that inform investment analysis and industry trend monitoring.
TELE Bio (NASDAQ: TELA) has appointed Greg Firestone as its new Chief Commercial Officer, effective May 20, 2024. Mr. Firestone, who has been with the company since 2017, will now oversee commercial operations, including key product launches, sales team training, market development, and strategic initiatives. His extensive experience includes executive roles in the healthcare sector and founding multiple companies. The appointment is viewed as a strategic move to enhance market share and operational efficiency as the company aims for strong year-end performance.
TELA Bio, Inc. announced the approval of inducement grants of restricted stock units to newly-hired employees. The grants cover 20,250 shares of common stock and were approved on May 6, 2024. The restricted stock units will vest over four years, contingent on the employees' continued service with TELA Bio.
TELA Bio, Inc. reported strong financial results for Q1 2024, with revenue reaching $16.6 million, a 39% increase from the same period in 2023. The company achieved its 13th consecutive quarter of over 35% year-over-year growth and increased full-year revenue guidance to $74.5 million to $76.5 million. Gross profit was $11.3 million, operating expenses rose to $23.7 million, resulting in a loss from operations of $4.8 million. However, a one-time gain of $7.6 million from the sale of assets to MiMedx helped offset the loss, leading to a net loss of $5.7 million.
FAQ
What is the current stock price of Tela Bio (TELA)?
What is the market cap of Tela Bio (TELA)?
